Home > A. Molecular pathology > Targeted therapy > Small molecules > abemaciclib
abemaciclib
Wednesday 14 December 2016
LY2835219
|WKP|
Abemaciclib is a CDK inhibitor selective for CDK4 and CDK6.
It is an investigational drug for various types of cancer developed by Eli Lilly. It was designated as a breakthrough therapy by the U.S. Food and Drug Administration in October 2015.
See also
CDK4/6 inhibitors
